Introduction
The substantia nigra pars reticulata (SNr) is a strategic point for integration of inputs from the "direct" and "indirect" pathways of the basal ganglia (Alexander and Crutcher, 1990) . It also provides a major output projection from the basal ganglia to the thalamus, where it influences the activity of the thalamocortical relay. Among the inputs to the SNr is a projection from histamine (HA)-containing neurons of the tuberomammillary nucleus (Panula et al., 1989) . Although there is limited information on the actions of HA in the SNr, HA has been implicated in the modulation of GABA release at striatonigral synapses (Garcia et al., 1997) and in the local regulation of motor functions (GarciaRamirez et al., 2004) . In Parkinson's disease (PD), there is an increase in HA levels and in the varicosity size and density of HA fibers in the SN (Anichtchik et al., 2000a) . Furthermore, H 3 R binding density is elevated in the SN in PD (Ryu et al., 1994; Anichtchik et al., 2000b Anichtchik et al., , 2001 and in rats after 6-OHDA lesions (Ryu et al., 1994; Anichtchik et al., 2000b Anichtchik et al., , 2001 .
Three HA receptors have been identified in the CNS, of which two, H 2 and H 3 , are found at high densities in the basal ganglia (Vizuete et al., 1997; Pillot et al., 2002) . H 3 binding sites are particularly abundant in the SNr, but there is only low expression of the mRNA for H 3 Rs (Pillot et al., 2002 ). These findings indicate that H 3 Rs are principally expressed by afferents to and not local projection neurons within the SN. Regions that express H 3 R mRNA and project to the SNr include the striatum, subthalamic nucleus, and raphe nuclei but not the dopaminergic neurons in the substantia nigra pars compacta (SNc)-ventral tegmental area (Pillot et al., 2002) . The H 3 R is predominantly a presynaptic receptor that has been shown to inhibit release of HA (Arrang et al., 1983) , glutamate (Brown and Reymann, 1996; Brown and Haas, 1999; Molina-Hernandez et al., 2001) , GABA (Garcia et al., 1997; Yamamoto et al., 1997; Arias-Montano et al., 2001) , norepinephrine (Schlicker et al., 1989 (Schlicker et al., , 1992 (Schlicker et al., , 1999 , dopamine (DA) (Schlicker et al., 1993) , acetylcholine (Arrang et al., 1995; Giorgetti et al., 1997; Prast et al., 1999) , and 5-hydroxytryptamine (5-HT) in cortex (Schlicker et al., 1988; Fink et al., 1990 ). The present study was designed to elucidate the role of H 3 receptors (H 3 Rs) in the SNr. We initially used immunohistochemical techniques to establish whether there is a comparable distribution of histaminergic and serotonergic processes in the SNr. We then used fast-scan cyclic voltammetry (FCV) at carbon-fiber microelectrodes (CFMs) to monitor in real time the modulation of electrically evoked 5-HT release in the SNr by H 3 R ligands.
Materials and Methods
Tissue preparation for immunohistochemistry. Adult male Wistar rats (150 -180 gm; Charles River Laboratories, Isaszeg, Hungary) were maintained for 1 week in a light-and temperature-controlled environment (lights on 5:00 A.M. to 7:00 P.M.; 22 Ϯ 1°C) and allowed access to food and water ad libitum. To enhance detection of histamine-containing processes, synthesis of brain histamine was stimulated (Schwartz et al., 1972; Prell et al., 1996) by L-histidine loading (6 mM, i.p.; n ϭ 3) 1 hr before transcardial perfusion with 50 ml of phosphate buffered 4% 1-ethyl-3(3-dimethylaminopropyl)-carbodiimide (EDCDI; Sigma, Poole, UK) under pentobarbital anesthesia (80 mg/kg); the brains were removed and immersed in EDCDI (4 d) followed by 2% paraformaldehyde (PFA) (1 d). For the immunohistochemical detection of serotonergic processes, animals (n ϭ 3) were perfused transcardially with 4% PFA in 0.1 M PBS under pentobarbital anesthesia (80 mg/kg); the brains were removed and postfixed in 2% PFA. All brains were infiltrated in 30% sucrose overnight; midbrain sections (25 m) were cut in the coronal plane using a freezing microtome (Leica, Vienna, Austria).
Immunohistochemistry. Pretreatment of sections included sequential incubation in 0.5% Triton X-100 (30 min), 0.5% H 2 O 2 (10 min), and 2% normal horse serum (30 min). The procedure used to detect histamineimmunoreactive processes required EDCDI fixation (Panula et al., 1984) . Serotonergic processes were identified with antibodies against the serotonin transporter (SERT) in PFA-fixed sections. Tyrosine hydroxylase (TH) immunoreactivity (IR) served to identify dopaminecontaining structures following either form of fixation.
For double-label immunohistochemical detection of HA-IR together with TH-IR, sections were initially incubated in rabbit anti-histamine (Panula et al., 1984) (1:12,000) for 72 hr at 4°C. Biotinylated donkey anti-rabbit IgG (1:1000; Jackson Laboratories, Bar Harbor, ME) and the ABC solution (1:1000; Vector Laboratories, Burlingame, CA) were used before amplification (Adams, 1992) with biotinylated tyramide (1:1000); sections were then incubated overnight at 4°C in Alexa 594 streptavidin (1:500; Molecular Probes, Eugene, OR). Subsequently, mouse anti-TH [monoclonal antibody (mAb) 22941, 1:1000; Incstar, Stillwater, MN] was applied for 48 hr at 4°C; this was visualized with Alexa 350 conjugated to goat anti-mouse IgG (1:500, overnight at 4°C; Molecular Probes).
For double-label immunohistochemical detection of SERT together with TH-IR, mouse anti-SERT (mAb 1564, 1:2000; Chemicon, Temecula, CA) was applied for 48 hr at 4°C and visualized using black silver-gold intensified nickel diaminobenzidine (SGI-NiDAB) as described previously (Kalló et al., 2001) . Subsequently, mouse anti-TH (mAb 22941, 1:1000; Incstar) was applied for 48 hr at 4°C and detected by the brown DAB reaction product. Previous studies (Liposits et al., 1986) have demonstrated that double-label peroxidase-based immunohistochemistry can be successfully performed using primary antibodies from the same species when the first reaction product is silver-gold intensified.
Sections were mounted, and a coverslip was fixed with DPX (a mixture of distyrene, tricresyl phosphate, and xylene; Fluka, Buchs, Switzerland) for the SGI-NiDAB/DAB sections or with Antifade (Molecular Probes) for the immunofluorescence sections and examined using an Axiophot microscope (Zeiss, Göttingen, Germany) equipped with a real-time Spot digital camera (Diagnostic Instruments, Sterling Heights, MI).
Slice preparation for FCV. Male Wistar rats (150 -220 gm) were anesthetized with halothane and decapitated, and their brains were removed. Midbrain slices were prepared according to methods described previously (Cragg et al., 1997b (Cragg et al., , 2002 . A block of midbrain was mounted onto a specimen plate with cyanoacrylate adhesive and placed in the doublewalled buffer tray in the Leica VT1000S vibratome. The buffer tray was then surrounded by ice and filled with ice-cold HEPES ringer containing the following (in mM): 120 NaCl, 5 KCl, 20 NaHCO 3 , 6.7 HEPES acid, 3.3 HEPES salt, 2 CaCl 2 , 2 MgSO 4 , 1.2 KH 2 PO 4 , and 10 glucose saturated with 95% O 2 /5% CO 2 . Slices 350 m thick were cut and maintained in individual vials in HEPES ringer for Ն 1 hr at room temperature before transferal to the recording chamber. The coordinates of midbrain slices containing the SNr correspond to anterior 3.2-4.2 mm of adult rat, according to the atlas of Paxinos and Watson (1982) . The slices were equilibrated with the superfusion medium of the recording chamber at 30 -32°C for an additional 30 min before the beginning of the experiment. The superfusion medium was a bicarbonate-buffered artificial CSF (aCSF) maintained at 30 -32°C and contained the following (in mM): 124 NaCl, 3.7 KCl, 26 NaHCO 3 , 2.4 CaCl 2 , 1.3 MgSO 4 , 1.3 KH 2 PO 4 , and 10 glucose with saturated 95% O 2 /5% CO 2 . Ca 2ϩ -free solutions included 1 mM EGTA and 2.4 mM MgCl 2 . Superfusion flow rate was ϳ1.5 ml/min.
Voltammetry and carbon fiber microelectrodes. All recordings were made using a Millar Voltammeter (P.D. Systems, West Molesey, UK) as described previously (Cragg et al., 1997a (Cragg et al., ,b, 2002 . The instrument was used as a three-electrode potentiostat, with an Ag/AgCl wire as the reference electrode and the stainless steel flow outlet of the bath as the auxiliary. Voltammograms were obtained in the simple triangle wave mode with a voltage ramp of Ϫ0.7 to ϩ1.3 V and then back to Ϫ0.7 V versus Ag/AgCl at a scan rate of 800 V/sec. The scan was switched out of circuit between scans. Sampling frequency was 8 Hz. Evoked extracellular concentrations of 5-HT ([5-HT] o ) were measured using FCV with CFMs beveled to a point (fiber tip diameter, ϳ6 m; exposed fiber length, ϳ30 m; MPB Electrodes, London, UK). CFMs were positioned 50 -100 m into the tissue with the aid of a binocular microscope.
Electrode calibrations were performed after the experiment in the recording chamber at 32°C using 0.25 M 5-HT made up in all experimental solutions. Calibration solutions were made immediately before use from stock solutions of 5-HT in 0.1 M HClO 4 . Electrode sensitivity was determined after use, and these postslice calibration factors were used to calculate Electrical stimulation. Concentric bipolar stimulating electrodes (FHC, Bowdoinham, ME) were used to electrically evoke 5-HT release in the SN. The stimulating electrode was positioned on the tissue surface ϳ50 -100 m from the CFM with the aid of a binocular microscope. Stimulus pulses (0.2 msec duration; 0.6 mA) were applied in trains of 20 pulses at 100 Hz at repeat intervals of 5 min; by this time, release is fully reproducible and can be maintained for Ն2 hr. In initial experiments to characterize 5-HT release, the dependence on pulse frequency and number was verified using either trains of 20 pulses at 10 -200 Hz in random order or 1-50 pulses at 100 Hz. (GYKI 52466) ] to make stock aliquots at 1000ϫ or 10,000ϫ final concentrations and stored at Ϫ20°C until required. Stock aliquots were diluted with aCSF to final concentration immediately before use and perfused for Ͼ7 min before data were included in drug analysis. D-AP-5, GYKI 52466 hydrochloride, tetrodotoxin (TTX), saclofen, ( S)-MCPG, citalopram hydrobromide, isamoltane hemifumarate, immepip dihydrobromide, and thioperamide maleate were obtained from Tocris Cookson (Bristol, UK). [1-(2-(Bis-(4-fluorophenyl)methoxy)ethyl)-4-(3 phenylpropyl)piperazine dihydrochloride] (GBR 12909) was obtained from Research Biochemicals International (Natick, MA). All other compounds were obtained from Sigma.
Drugs. Drugs were dissolved in water, aqueous alkali [( S)-(Ϯ)-amino-
Data analysis and statistics. Data were acquired and analyzed using Strathclyde Whole Cell Program (University of Strathclyde, Glasgow, Scotland, UK). Current sampled at the 5-HT oxidation peak potential was measured from the baseline of each voltammogram to provide profiles of [5-HT] o versus time. This procedure minimizes inclusion of contributions from other electroactive and nonelectroactive species to the neurotransmitter oxidation current (Rice and Nicholson, 1989; Venton et al., 2003) . Illustrated data represented are means Ϯ SEM (n ϭ number of observations). Three to five animals were used in each experiment. Illustrated voltammograms have background current subtracted. Comparisons for differences in means were assessed for parametric data by one-way ANOVA followed by post hoc multiple comparison t tests (Dunnett's); nonparametric or normalized data were compared by unpaired Mann-Whitney U tests (M-WU) or where appropriate by Kruskal-Wallis variance analysis followed by Dunn's t tests. Concentration-response curves were generated with GraphPad Prism software (GraphPad Software, San Diego, CA) using nonlinear regression to a sigmoidal doseresponse (variable slope) from which IC 50 values were obtained and, where appropriate, compared statistically. Statistical significance was considered as p Ͻ 0.05.
Results

Identification of HA and 5-HT immunoreactivity in SNr
In sections from rats perfused with EDCDI, abundant processes immunoreactive for HA or TH were observed in the SNr (Fig.  1 A-C) . Varicosities immunoreactive for HA were found in the vicinity of TH-immunoreactive processes (Fig. 1C) . After PFA fixation, processes immunoreactive for SERT were found throughout the SNr (Fig. 1 D, E) . As in the case of HA-IR, SERTimmunoreactive varicosities were found in the vicinity of THimmunoreactive processes (Fig. 1 E) . By reference to THimmunopositive processes, we conclude that within the SNr, there is similarity in the distribution of putative terminal fields containing HA or 5-HT. Analysis of the direct ultrastructural interactions between HA-IR and 5-HT-IR is not currently feasible because of the different methodological conditions required to reveal them.
Electrochemical characterization of 5-HT release in SNr
Electrical stimulation (20 pulses, 100 Hz) in SNr evoked the release, followed by the rapid removal, of an electroactive substance that could be identified as 5-HT. The voltammogram of the released substance was readily identified as 5-HT because of an oxidation peak potential at approximately ϩ600 mV (vs Ag/ AgCl) and a dual reduction profile with peak potentials at ϳ0 and Ϫ680 mV (Fig. 2 A, B) , identical to those obtained in calibration with application of 5-HT (Fig. 2C) . The substance can readily be distinguished from DA (Fig. 2 D) by the characteristic doublereduction current profile for 5-HT as noted previously in SNr (Davidson and Stamford, 1996; Cragg et al., 1997b; Iravani and Kruk, 1997; Bunin et al., 1998) . Furthermore, it has been identified previously that the primary substance detected in rat SNr using this method is 5-HT and not DA (Cragg et al., 1997b; Iravani and Kruk, 1997; Bunin et al., 1998) .
To further confirm the identity of the electrochemical signal as 5-HT and not DA, uptake inhibitors for the SERT and the DA transporter (DAT) were applied. Bath application of the SERT inhibitor citalopram (75 nM) prolonged the extracellular lifetime of 5-HT and significantly enhanced (Fig. 3A) (M-WU; p Ͻ 0.001; n ϭ 28) as shown previously with SERT inhibitors in the SNr (Iravani and Kruk, 1997; Bunin et al., 1998) . Conversely, application of the DAT inhibitor GBR 12909 (1 M) had no effect on the lifetime or peak concentration of the detected substance, 5-HT (Fig. 3B ) (M-WU; p Ͼ 0.05; n ϭ 14).
Ionic and depolarization sensitivity
Evoked release of 5-HT was apparently abolished by inhibition of voltage-gated Na ϩ channels (Na v ϩ ) by TTX (1 M) (Fig. 3C ) (M-WU; p Ͻ 0.001; n ϭ 18 -22) and reversibly abolished with application of Ca 2ϩ -free-EGTA-containing aCSF (Fig. 3D ) (M-WU; p Ͻ 0.001; n ϭ 12). Mean peak-evoked [5-HT] o varied significantly with frequency across the range of 10 to 200 Hz (20 pulses; one-way ANOVA; p Ͻ 0.001) in a biphasic manner that indicated frequency dependence at Ͻ100 Hz but a diminished ability to follow frequencies greater than this (Fig. 3E) ( post hoc Dunnett's t tests vs 10 Hz: 20 -100 Hz, p Ͻ 0.001-0.05; 200 Hz, p Ͼ 0.05). Mean peak-evoked [5-HT] o varied significantly with the number of pulses in a train (100 Hz; one-way ANOVA; p Ͻ 0.001) as observed previously (Iravani and Kruk, 1997; Bunin et al., 1998) , showing a linear dependence at pulse numbers Ͻ30 (Fig. 3F ) (linear regression over 0 -30 pulses; y-intercept ϭ 0; R 2 ϭ 0.97). Trains of 20 pulses at 100 Hz were selected for all subsequent pharmacological investigations.
H 3 R effects on 5-HT release in the SNr
Mean peak evoked [5-HT] o (20 pulses at 100 Hz) was significantly attenuated by bath application of selective H 3 R agonists ( R)-(-)-␣-methylhistamine (R-mHA) or immepip (Fig. 4 A, B) (Kruskal-Wallis, p Ͻ 0.001; n ϭ 14 -15). Each drug demonstrated a concentration-dependent inhibition of 5-HT release of up to 49 Ϯ 5% of control by R-mHA (1 M; n ϭ 14) and to 39 Ϯ 3% by immepip (5 M; n ϭ 15) with IC 50 values of 23 nM (R-mHA; 95% confidence interval range, 13-43 nM; Hill slope, Ϫ1.1) and 43 nM, respectively (immepip; 95% confidence interval range, 20 -95 nM; Hill slope, Ϫ0.73, not significantly different from 1.0). These IC 50 values were not significantly different from one another ( p Ͼ 0.05).
To confirm that the actions of these H 3 R agonists were attributable to selective agonism at H 3 Rs, their effects were assessed in the presence of a selective H 3 R antagonist, thioperamide. Whereas R-mHA (100 nM) reduced mean peak [5-HT] o from 100 Ϯ 2 to 52 Ϯ 4% without thioperamide ( (Fig. 5B ) (10 M; 108 Ϯ 5% in thioperamide only vs 104 Ϯ 6% in thioperamide plus immepip; n ϭ 16 -22; M-WU; p Ͼ 0.05). In contrast, the effect of R-mHA (1 M) was not prevented by the presence of a 5-HT 1B receptor antagonist, isamoltane (Fig. 5C) (1 M; 111 Ϯ 11.0% in isamoltane only vs 54 Ϯ 7% in isamoltane plus R-mHA; M-WU; p Ͻ 0.001; n ϭ 12-21) at a concentration of isamoltane previously observed to block 5-HT 1B agonist effects (Davidson and Stamford, 1996) .
Direct or indirect H 3 R effects?
Studies were undertaken to explore whether H 3 R-mediated inhibition of 5-HT release might be attributable to H 3 Rs present on GABAergic or glutamatergic inputs to 5-HT terminals rather than on the 5-HT terminals themselves. The effects of the H 3 R agonist R-mHA were investigated in the presence of mixtures of either GABA or glutamate receptor antagonists (ionotropic and metabotropic). Despite the application of the GABA receptor antagonists picrotoxin (PTX; GABA A receptor antagonist, 100 M) and saclofen (GABA B receptor antagonist, 50 M), R-mHA (1 M) significantly inhibited mean peak o from 106 Ϯ 6 to 27 Ϯ 7% (Fig. 6 A) (M-WU; p Ͻ 0.001; n ϭ 14 -21). Inhibition of 5-HT release via the H 3 R also prevailed when R-mHA was applied in the presence of the glutamate receptor antagonists D-AP-5 (NMDA receptor antagonist, 50 M), GYKI 52466 (noncompetitive AMPA/kainate receptor antagonist, 10 M), and ( S)-MCPG (Fig. 6 B) (nonselective group I/II metabotropic glutamate receptor antagonist, 200 M; 105 Ϯ 6% in glutamate antagonists vs 30 Ϯ 4% in glutamate antagonists plus R-mHA; M-WU; p Ͻ 0.001; n ϭ 16 -26). Statistical comparison of R-mHA effects in the absence versus the presence or either GABA or glutamate receptor antagonists (using recording sites matched for concentration of 5-HT released in drug-free controls) does not reveal a significant effect of synaptic block on R-mHA effects (M-WU; n ϭ 14 -16).
Discussion
5-HT detection in SNr
The evoked neurotransmitter release detected in the SNr in this study was Na V ϩ and Ca 2ϩ dependent and sensitive to depolarization frequency and pulse number, as previously reported for 5-HT exocytosis in the SNr (O'Connor and Kruk, 1991; Iravani and Kruk, 1997; Bunin et al., 1998) . It is well established that 5-HT is the predominant monoamine detected by FCV at CFMs in the rat SNr (Cragg et al., 1997b; Iravani and Kruk, 1997; Bunin et al., 1998) ; this differs from the guinea pig SNr in which 5-HT is detected far less frequently and DA predominates (Cragg et al., 1997b) . Several lines of evidence indicate that the signal monitored in this study was indeed caused by the release of 5-HT. First, immunocytochemistry showed that serotonergic processes are abundant throughout the SNr. Second, the voltammograms resulting from the evoked release indicated that the released substance was identical in its electrochemical profile to the indoleamine 5-HT and not to the catecholamine DA. Third, inhibition of the SERT but not the DAT prolonged the extracellular lifetime and enhanced the peak amplitude of the 5-HT-like signal. These observations indicate that the electrochemical signal was attributable to 5-HT, with negligible contribution from DA, and confirm that the SERT participates in [5-HT] o regulation in the SNr as reported previously (Iravani and Kruk, 1997; Bunin et al., 1998) .
H 3 R control of 5-HT release in the SNr
In the present study, the evoked release of 5-HT in SNr was potently inhibited by the H 3 R agonists R-mHA or immepip to levels that were Ͻ50% of those seen in controls. This attenuation of 5-HT release was dose dependent, with IC 50 values for R-mHA and immepip that were consistent with previously reported values for H 3 R efficacy in guinea pig ileum (Hew et al., 1990 ) and inhibition of striatal glutamate release (Molina-Hernandez et al., 2001) , respectively. The inhibition of 5-HT release in SNr by activation of H 3 Rs was confirmed further by experiments with the selective H 3 R antagonist thioperamide. Previous application of thioperamide prevented the inhibition of 5-HT release by R-mHA or immepip. In contrast, the action of these H 3 R agonists was not modified by antagonism of 5-HT 1B receptors, a 5-HT receptor type that has been shown to participate in presynaptic autoreceptor control of 5-HT release elsewhere in the brain (Barnes and Sharp, 1999) . This observation indicates that the actions of the H 3 agonists were not attributable to effects on 5-HT autoreceptors.
The potent inhibition of 5-HT signaling by H 3 Rs identifies a powerful role for these abundant receptors in the SNr (Pillot et al., 2002) . Although H 3 R-dependent regulation of 5-HT signal- ing has been identified previously in rat cortex (Schlicker et al., 1988; Fink et al., 1990) , the current data are the first to identify a comparable mechanism within the basal ganglia.
H 3 R on GABA and glutamate synapses To date, there is no anatomical information available regarding the specific identity of the neurons that express H 3 Rs in the SNr and the ultrastructural location of these receptors. Thus, the synaptic circuitry by which H 3 Rs detected in the SNr by radioligand binding (Pillot et al., 2002) can regulate 5-HT release is unidentified. Because in situ hybridization for mRNA for H 3 Rs reveals only low expression within the SN (Pillot et al., 2002 ), the abundant H 3 Rs in SN are unlikely to be expressed or localized on DA neurons in the SNc or on local or projection neurons within the SNr. However, moderate H 3 R transcript expression has been identified in the raphe nuclei (Pillot et al., 2002) ; therefore, it is plausible that the H 3 Rs are synthesized by 5-HT neurons and located on 5-HT terminals.
Because a similar level of H 3 R mRNA expression has also been identified in the dorsal striatum, subthalamic nucleus, and pedunculopontine nucleus (Pillot et al., 2002) , regions that send major non-5-HT projections (e.g., GABAergic or glutamatergic) to the SNr, we evaluated whether such inputs to the SNr might be involved in H 3 R-mediated inhibition of 5-HT release. Previous evidence has indicated that H 3 Rs in the SNr inhibit GABA release (Garcia et al., 1997; Garcia-Ramirez et al., 2004) . The possibility that H 3 Rs present on GABAergic or glutamatergic terminals in the SNr contribute to H 3 R-mediated regulation of 5-HT release was investigated using receptor antagonists for GABA or glutamate. H 3 R-mediated inhibition of 5-HT release was preserved in the presence of GABA-glutamate synaptic block; thus, a role for H 3 Rs on GABA or glutamate terminals in this context seems unlikely. Furthermore, because in the absence of H 3 R agonists neither GABA nor glutamate antagonists significantly modified o , the control of 5-HT release in this paradigm does not appear to be under direct control by glutamate or GABA synapses. Whether the inhibitory action of H 3 R agonists on GABA release in the SNr (Garcia et al., 1997; Garcia-Ramirez et al., 2004) is mediated via effects on 5-HT release remains to be tested.
The present results raise the possibility that the H 3 R-mediated inhibition of 5-HT release is attributable to a direct action on 5-HT terminals via H 3 Rs. This regulation of 5-HT release is noteworthy in light of reports indicating little, if any, regulation of 5-HT release in the SNr by 5-HT 1B autoreceptors (Nissbrandt et al., 1992; Iravani and Kruk, 1997) . Despite a high density of 5-HT 1B receptors in the SNr, they are observed predominantly on striatonigral GABAergic terminals from the striatum rather than on serotonergic terminals (Boschert et al., 1994; Sari et al., 1999 ). It appears that 5-HT release in the SNr is not regulated by 5-HT receptors; this is not the case in the raphe nuclei where a plurality of 5-HT receptors perform autoreceptor-like functions (Stamford et al., 2000; Hopwood and Stamford, 2001 ). H 3 R-mediated control of 5-HT release in SNr may provide a substitute mechanism for presynaptic inhibition of 5-HT release.
Conclusions
The present findings indicate a similar distribution of histaminergic and serotonergic processes in the SNr. Double-label immunohistochemical studies at the electronmicroscopic level will be required to establish whether there are histaminergic synapses on serotonergic terminals at this site. The results of the FCV studies are certainly consistent with an interaction between histaminergic and serotonergic systems. Thus, the data indicate that H 3 Rs mediate presynaptic regulation of 5-HT release in the SNr. The location of the H 3 Rs in question does not appear to involve either GABA or glutamate synapses; nevertheless, their possible presence on the terminals of other (e.g., cholinergic) projections to the SN cannot be discounted. The notion that the H 3 Rs mediating inhibition of 5-HT release are located directly on 5-HT axons is consistent with the expression of the mRNA for H 3 R in the raphe nuclei (Pillot et al., 2002) and the similar anatomical distribution of HAimmunoreactive and 5-HT-immunoreactive varicosities in the SNr. Given the apparent lack of autoreceptor control of 5-HT release at this site (Nissbrandt et al., 1992; Iravani and Kruk, 1997) , H 3 R activation may be a key mechanism for 5-HT regulation.
The significance of H 3 R-mediated control of 5-HT release depends on the function(s) of 5-HT in the SNr. Serotonergic inputs to the SNr (Corvaja et al., 1993; Moukhles et al., 1997) have the potential to modify motor output signals (Jacobs and Fornal, 1993; Rick et al., 1995) . Moreover, 5-HT is a target for therapeutic intervention regarding unwanted side effects associated with long-term DA replacement in PD, such as the wearingoff phenomenon and L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (Nicholson and Brotchie, 2002) . 5-HT 2C receptors on SNr projection neurons are excitatory (Rick et al., 1995) ; their binding is increased in the SNr of PD patients with L-DOPA-induced dyskinesia, suggesting a possible compensatory upregulation of receptors in response to decreased endogenous ligand (Fox and Brotchie, 2000) . In this context, it should be noted that the selective serotonin reuptake inhibitor, fluoxetine, reduces dyskinesias in PD patients (Durif et al., 1995) .
The capacity of HA to regulate 5-HT transmission in the SNr via H 3 Rs may provide an attractive nondopaminergic target for improving therapies for PD. Identifying novel approaches to manipulate 5-HT neurotransmission may help to enhance the efficacy of current treatments not only for PD but also for mood disorders such as depression and anxiety, in which serotonergic manipulation is pivotal.
